Abstract:Abstract Background: Cell-type-specific super enhancers, or large clusters of mediator-rich enhancers, are highly transcribed regions of the genome with key functions in the maintenance of cell identity and control. These regulatory elements are easily perturbed and enriched for disease-associated sequence variation. Identification of disease-associated super-enhancers and investigation of their sequence variants may help identify important, biologically relevant associations previously overlooked by genome-wide studies. Thus, we sought to identify variants within ovarian tissue specific super-enhancers and investigate their association with epithelial ovarian cancer (EOC) susceptibility. Methods: We utilized genotype data from a European population of ∼11,000 invasive EOC cases and 22,000 healthy controls from the Ovarian Cancer Association Consortium. A public catalog of 478 super-enhancers, identified by peak histone H3K27ac ChIP-seq signal in ovarian tissue, was used to identify 72,116 variants located within 344 super-enhancer regions. Unconditional logistic regression (log-additive model) was used to assess individual SNP-EOC risk associations. Additionally, we reviewed associations within 500 kb of super-enhancer regions to identify proximal associated variants. When LD structure indicated, we employed conditional analysis to determine independence of the super-enhancer signal. Gene-EOC risk associations were assessed with the Admixture Maximum Likelihood (AML) test and Sequence-Kernel Association Test (SKAT) for the combined effect of common and rare (MAF<0.01) variants. Models were adjusted for population stratification using the first five principal components. To adjust for multiple comparisons, a false discovery rate of 10% was used. Results: The most significant SNP observed was rs147487657 (p = 7.7×10−6) on locus 2q37.3 in the HDAC4 gene and there were an additional 12 SNPs with p<1.0×10−4, although not significant at 10% FDR. Gene-level analyses identified two super-enhancers significantly associated with EOC risk. An enhancer at the previously reported 2q31 locus, containing HOXD8 and HOXD-AS2, associated (SKAT p = 4.3×10−5; AML p<0.001) with the top SNP located within the 5′UTR of HOXD8 transcription factor (rs847163 (T>C); p<2.08×10−5). Conditional analysis did not identify an independent association within the super-enhancer region. The second EOC-associated super-enhancer identified was at locus 1q32 (SKAT p = 0.00052, AML p = 0.001) containing the CSRP1 gene. There were 6 SNPs with p<0.001 and 16 SNPs with p<0.01, all were inversely associated with risk and consistent with the top hit at rs927901 T>C (OR = 0.94; 95% CI: 0.90-0.97; p = 2.1×10−4). Associations varied by histologic subtype, possibly due to variance in disease relevant super-enhancer cell-type.Conclusion: These findings suggest germline variation within super-enhancer regions may contribute to EOC susceptibility Citation Format: Brett M. Reid, Jennifer Permuth-Wey, Y. Ann Chen, Hui-Yi Lin, Alvaro Monteiro, Zhihua Chen, Andrew Berchuck, Georgia Chenevix-Trench, Jennifer Doherty, Simon Gayther, Ellen L. Goode, Edwin Iversen, Leigh Pearce, Paul Pharoah, Catherine Phelan, Susan Ramus, Mary Anne Rossing, Joellen Schildkraut, Thomas Sellers, on behalf of the Ovarian Cancer Association Consortium. Variants within super-enhancer regulatory elements associate with epithelial ovarian cancer risk. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4634. doi:10.1158/1538-7445.AM2015-4634

Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes.

Pathway And Gene Set Analyses For Epithelial Ovarian Cancer (Eoc) Genome-Wide Association Study (Gwas)

Exome Genotyping Arrays to Identify Rare and Low Frequency Variants Associated with Epithelial Ovarian Cancer Risk.

A Genome-Wide Association Study Identifies a New Ovarian Cancer Susceptibility Locus on 9P22.2.

Microrna Processing and Binding Site Polymorphisms Are Not Replicated in the Ovarian Cancer Association Consortium

Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci

Abstract 4633: Evidence That Long Non-Coding RNA Variants Associate with Epithelial Ovarian Cancer Risk

Genome-Wide Association Study Of Copy Number Variations In Serous Epithelial Ovarian Cancer Susceptibility

Abstract 6065: Patterns of Dysregulated Coding and Noncoding Gene Expression in High-Grade Serous Ovarian Carcinomas

Identification and Molecular Characterization of a New Ovarian Cancer Susceptibility Locus at 17Q21.31.

STAT3 Polymorphisms May Predict an Unfavorable Response to First‐line Platinum‐based Therapy for Women with Advanced Serous Epithelial Ovarian Cancer

Abstract 1562: Germline Polymorphisms in Cancer Stem Cell Genes Associate with Survival among Women with High-Grade Serous Ovarian Cancer

Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium

A Genome-Wide Association Study Identifies Susceptibility Loci for Ovarian Cancer at 2q31 and 8Q24.

Abstract 4579: Variants in Long Non-Coding RNAs Are Associated with Epithelial Ovarian Cancer Risk in a Pooled Analysis of Three Genome-Wide Association Studies.

Supplementary Figures 1-5, Tables 1-8 from Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium

An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients

Network-Based Integration of Gwas and Gene Expression Identifies A Hox-Centric Network Associated with Serous Ovarian Cancer Risk

Abstract 4634: Variants Within Super-Enhancer Regulatory Elements Associate with Epithelial Ovarian Cancer Risk

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer

Assessment of Variation in Immunosuppressive Pathway Genes Reveals TGFBR2 to Be Associated with Risk of Clear Cell Ovarian Cancer.